H.Res. 484 · 117th Congress

Expressing the sense of the House of Representatives that the United States should not waive intellectual property rights relating to COVID-19 vaccines or treatments.

Stage
In committee
Sponsor
Mariannette Miller-Meeks
Introduced
2021-06-17
Latest action
2022-11-01 · Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Subjects

Infectious and parasitic diseases
Health technology, devices, supplies
Emergency medical services and trauma care
Competitiveness, trade promotion, trade deficits
Commerce
Cardiovascular and respiratory health
Immunology and vaccination
Intellectual property
Manufacturing